WO2005076819A3 - Chlorite in the treatment of neurodegenerative disease - Google Patents

Chlorite in the treatment of neurodegenerative disease Download PDF

Info

Publication number
WO2005076819A3
WO2005076819A3 PCT/US2005/002469 US2005002469W WO2005076819A3 WO 2005076819 A3 WO2005076819 A3 WO 2005076819A3 US 2005002469 W US2005002469 W US 2005002469W WO 2005076819 A3 WO2005076819 A3 WO 2005076819A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative disease
chlorite
treatment
cell activation
immune cell
Prior art date
Application number
PCT/US2005/002469
Other languages
French (fr)
Other versions
WO2005076819A2 (en
Inventor
Michael S Mcgrath
Original Assignee
Univ California
Michael S Mcgrath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34860199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005076819(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Michael S Mcgrath filed Critical Univ California
Priority to AU2005213300A priority Critical patent/AU2005213300B2/en
Priority to EP05722556.7A priority patent/EP1711191B1/en
Priority to CN2005800037236A priority patent/CN101102781B/en
Priority to JP2006552151A priority patent/JP5072367B2/en
Priority to CA2554511A priority patent/CA2554511C/en
Publication of WO2005076819A2 publication Critical patent/WO2005076819A2/en
Publication of WO2005076819A3 publication Critical patent/WO2005076819A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.
PCT/US2005/002469 2004-02-03 2005-01-25 Chlorite in the treatment of neurodegenerative disease WO2005076819A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005213300A AU2005213300B2 (en) 2004-02-03 2005-01-25 Chlorite in the treatment of neurodegenerative disease
EP05722556.7A EP1711191B1 (en) 2004-02-03 2005-01-25 Chlorite in the treatment of amyotrophic lateral sclerosis
CN2005800037236A CN101102781B (en) 2004-02-03 2005-01-25 Chlorite in the treatment of neurodegenerative disease
JP2006552151A JP5072367B2 (en) 2004-02-03 2005-01-25 Chlorous acid in the treatment of neurodegenerative diseases
CA2554511A CA2554511C (en) 2004-02-03 2005-01-25 Chlorite in the treatment of neurodegenerative disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54157604P 2004-02-03 2004-02-03
US60/541,576 2004-02-03

Publications (2)

Publication Number Publication Date
WO2005076819A2 WO2005076819A2 (en) 2005-08-25
WO2005076819A3 true WO2005076819A3 (en) 2006-04-13

Family

ID=34860199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/002469 WO2005076819A2 (en) 2004-02-03 2005-01-25 Chlorite in the treatment of neurodegenerative disease

Country Status (7)

Country Link
US (5) US7105183B2 (en)
EP (2) EP1711191B1 (en)
JP (3) JP5072367B2 (en)
CN (2) CN102423318B (en)
AU (1) AU2005213300B2 (en)
CA (2) CA2554511C (en)
WO (1) WO2005076819A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005510524A (en) * 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド Treatment of neurodegenerative disorders by modulating the polyamine pathway
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
ATE473443T1 (en) * 2004-07-16 2010-07-15 Gyros Patent Ab GRADING OF IMMUNE RESPONSES
US20060264783A1 (en) 2005-05-09 2006-11-23 Holmes Elizabeth A Systems and methods for monitoring pharmacological parameters
CN101253409A (en) * 2005-08-02 2008-08-27 埃克斯生物科技公司 Diagnosis, treatment, and prevention of vascular disorders using IL-1alpha autoantibodies
JP5371443B2 (en) 2005-12-22 2013-12-18 ニューラルタス ファーマシューティカルズ，インコーポレイテッド Chlorite formulations and methods and uses of this preparation
AU2013234421B2 (en) * 2005-12-22 2015-08-27 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US8007999B2 (en) 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (en) * 2006-05-22 2012-07-18 埃克斯生物科技公司 Treatment of cancer with anti-IL-1[alpha] antibodies
US20080113391A1 (en) 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
FR2910811B1 (en) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera USE OF RILUZOLE AND ITS DERIVATIVES FOR MANUFACTURING NEW DRUGS
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
PL2285409T3 (en) * 2008-05-30 2016-10-31 Il-1 alpha antibodies
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
BR112012002333A2 (en) * 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc method of reducing side effects and method of enhancing the effect of an immunomodulator administered to a subject in need thereof; methods for treating disease associated with overactivation of monocytes to activated macrophages, type II diabetes or related complications, disease associated with migration of activated monocytes or macrophages, disease associated with overproduction of scd14 and / or scd163 by activated macrophages; sodium chloride compound; pharmaceutical composition; method for diagnosing a macrophage-related disease in a subject; and method for determining the effectiveness of treatment with an oxidizing agent for macrophage related disease in a subject.
BR112012009196B1 (en) 2009-10-19 2021-03-30 Labrador Diagnostics Llc SYSTEM FOR MODELING THE PROGRESSION OF A DISEASE WITHIN A POPULATION
WO2011111043A1 (en) * 2010-03-10 2011-09-15 Yeda Research And Development Co. Ltd Cellular blood markers for early diagnosis of als and for als progression
PT2582391T (en) 2010-06-18 2019-01-11 Xbiotech Inc Arthritis treatment
PT2605771T (en) * 2010-08-16 2018-07-09 Allergan Inc Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
ES2622482T3 (en) 2010-08-23 2017-07-06 Xbiotech, Inc Neoplastic disease treatment
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127A (en) 2011-09-23 2018-08-17 埃克斯生物科技公司 Cachexia is treated
CA2857604A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
KR20200140400A (en) * 2012-08-31 2020-12-15 파이브 프라임 테라퓨틱스, 인크. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA2945179A1 (en) * 2014-05-16 2015-11-19 Michael S. Mcgrath Methods and compositions for treatment of macrophage-related disorders
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
WO2017079161A2 (en) 2015-11-02 2017-05-11 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
CN110382001A (en) 2017-02-16 2019-10-25 埃克斯生物科技公司 The treatment of suppurative hidradenitis
JP7119017B2 (en) 2020-03-13 2022-08-16 本田技研工業株式会社 Straddle-type electric vehicle
WO2023225125A1 (en) * 2022-05-19 2023-11-23 Neuvivo, Inc. Biomarkers for neurogenerative disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725437A (en) * 1985-05-02 1988-02-16 Oxo Chemie Gmbh Aqueous chlorite matrix solution

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213389A1 (en) * 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne STABILIZED ACTIVATED OXYGEN AND MEDICINAL PRODUCTS CONTAINING THIS STABILIZED ACTIVATED OXYGEN
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
US5051414A (en) * 1989-08-03 1991-09-24 Dupont Merck Pharmaceutical Company Inhibition of HIV and other retroviruses by polyoxoanions
DE4208828A1 (en) 1992-03-19 1993-09-23 Oxo Chemie Gmbh USE OF A CHEMICALLY STABILIZED CHLORITE MATRIX FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV INFECTIONS
US6099855A (en) * 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
ES2217582T3 (en) * 1997-10-06 2004-11-01 Oxo Chemie Ag USE OF A CHEMICALLY STABILIZED CHLORITE DISSOLUTION TO INHIBIT A SPECIFIC IMMUNE RESPONSE OF AN ANTIGEN.
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP2001078775A (en) * 1999-09-14 2001-03-27 Kokuritsu Seishin Shinkei Center Agent for controlling function of macrophage
CN1433481A (en) * 1999-11-30 2003-07-30 奥克索化学有限公司 Evaluating and predicting chinical outcomes by gene expression analysis
US6685754B2 (en) 2001-03-06 2004-02-03 Alchemix Corporation Method for the production of hydrogen-containing gaseous mixtures
JP2005510524A (en) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド Treatment of neurodegenerative disorders by modulating the polyamine pathway
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725437A (en) * 1985-05-02 1988-02-16 Oxo Chemie Gmbh Aqueous chlorite matrix solution

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MILLER T.M. ET AL: "Treating Neurodegenerative Diseases with Antibiotics", SCIENCE, vol. 307, January 2005 (2005-01-01), pages 361 - 362, XP002994599 *

Also Published As

Publication number Publication date
US7105183B2 (en) 2006-09-12
AU2005213300A1 (en) 2005-08-25
EP1711191A4 (en) 2008-12-17
US20050181068A1 (en) 2005-08-18
CA2838392A1 (en) 2005-08-25
EP2574342B1 (en) 2018-03-07
CN102423318B (en) 2015-09-09
AU2005213300B2 (en) 2011-06-16
US20170065634A1 (en) 2017-03-09
CA2554511C (en) 2016-01-19
CA2554511A1 (en) 2005-08-25
US8029826B2 (en) 2011-10-04
US9364501B2 (en) 2016-06-14
US20060159775A1 (en) 2006-07-20
JP5797083B2 (en) 2015-10-21
JP2007520554A (en) 2007-07-26
JP2015205901A (en) 2015-11-19
CN102423318A (en) 2012-04-25
JP2012067110A (en) 2012-04-05
US20120295296A1 (en) 2012-11-22
CN101102781A (en) 2008-01-09
EP1711191B1 (en) 2014-03-19
CN101102781B (en) 2012-06-20
US20110053186A1 (en) 2011-03-03
EP2574342A1 (en) 2013-04-03
EP1711191A2 (en) 2006-10-18
WO2005076819A2 (en) 2005-08-25
CA2838392C (en) 2017-04-04
JP5072367B2 (en) 2012-11-14

Similar Documents

Publication Publication Date Title
WO2005076819A3 (en) Chlorite in the treatment of neurodegenerative disease
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
CY1111359T1 (en) Memantine for the treatment of mild to moderate ALZHEIMER
WO2004004658A3 (en) Methods and compositions relating to isoleucine boroproline compounds
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
WO2005003766A3 (en) Methods of regulating metabolism and mitochondrial function
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2007038115A3 (en) Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2005027839A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2008027912A3 (en) Prediction of an agent's or agents' activity across different cells and tissue types
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2007014943A3 (en) Therapy for neurological diseases
WO2010041252A3 (en) Use of a cinnamon bark extract for treating amyloid-associated diseases
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
PL1979521T3 (en) Novel method for impregnating a textile surface
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2006121995A3 (en) Methods for treating nephrolithiasis
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2008109521A3 (en) Method of treatment using atranorin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005213300

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2554511

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005722556

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580003723.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006552151

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005213300

Country of ref document: AU

Date of ref document: 20050125

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005213300

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3180/CHENP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005722556

Country of ref document: EP